darzalex approval - Yahoo Search Results

Ads
related to: darzalex approval
$0 Co-Pay Info - Ph+ CML-CP Prescription Info - 3L Treatment

3l-cml-treatment.com/hcp/resources
Talk To Your Patients About Third Line Option that May Work For Them. Visit The Website. Diagnosing Ph+ CML-CP Patients? See A Third-Line Treatment Option That May Help.
Types: Unmet Needs In CML, Treatment Option, $0 Co-Pay Information, Medication Information
Treatment Option
Visit The Physician Website To

Learn More About This Treatment.

Mechanism Of Action
Learn How To Treat Patients

With Ph+ CML-CP Today.

Efficacy Information
Physicians, See How This Treatment

May Help Your Patients Today.

Safety Profile
Physicians, See Important Safety

Information About This Treatment.

Unmet Needs In CML
Are Your Patients Experiencing

Intolerance? Learn About Treatment.

$0 Co-Pay Information
Patients With Private Insurance

Could Save On Their Prescription.
DARZALEX® (daratumumab) - Official Patient Site

www.darzalex.com
Important Information About Treatment With DARZALEX®. Talk With Your Healthcare Provider to Learn More.
Watch Patient Stories · Caregiver Support · Prescription Assistance · Official Patient Site
DARZALEX® Side Effects
About DARZALEX®
Important Safety Info
Preparing For Treatment

Search results

- Medicare Negotiation Undercuts Biotech Stocks Regeneron, Halozyme
  Investor's Business Daily· 1 year ago
  Confusion over new Medicare negotiating plans sent Regeneron Pharmaceuticals and Halozyme...
- Drugmakers go under the skin, skirting early US Medicare price negotiations
  Reuters via Yahoo Finance· 10 months ago
  Injectable versions of some widely-used cancer drugs including Johnson & Johnson's blockbuster...
- Halozyme (HALO) Stock Rises 35% in the Year so Far: Here's Why
  Zacks via Yahoo Finance· 2 years ago
  Halozyme (HALO) is gaining on its proprietary drug delivery technology, ENHANZE. It expects strong...
- Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2024 Earnings Call Transcript
  Insider Monkey via Yahoo Finance· 3 weeks ago
  Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2024 Earnings Call Transcript May 7, 2024 Halozyme...
- Halozyme (HALO) Q1 Earnings Disappoint, Revenues Rise Y/Y
  Zacks via Yahoo Finance· 1 year ago
  Halozyme Therapeutics, Inc. HALO reported first-quarter 2023 adjusted earnings of 47 cents per...
- Genmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcript
  Insider Monkey via Yahoo Finance· 4 weeks ago
  Genmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcript May 2, 2024 Genmab A/S reports earnings...
- Halozyme (HALO) Q2 Earnings & Revenues Beat, 2023 View Raised
  Zacks via Yahoo Finance· 10 months ago
  Halozyme (HALO) shares rise 4% in the after-market trading hours on better-than-expected...
- HALO Stock: Halozyme Gets Under Your Skin To Deliver Blockbuster Drugs And Booming Growth
  Investor's Business Daily· 2 years ago
  Halozyme's under-the-skin technology helps deliver some of the biggest moneymaking injections,...
- Halozyme Therapeutics (HALO) Down 3.8% Since Last Earnings Report: Can It Rebound?
  Zacks via Yahoo Finance· 9 months ago
  It has been about a month since the last earnings report for Halozyme Therapeutics (HALO). Shares...
- GSK cancer drug Blenrep gets surprise trial win
  BioPharma Dive via Yahoo Finance· 6 months ago
  One year after the U.K. drugmaker withdrew the multiple myeloma drug from the U.S. market because of negative data, new study results might crack open...